ALS Research Forum
The mission of the ALS Research Forum is to help accelerate development of new therapies for amyotrophic lateral sclerosis, by providing a trustworthy, open-access forum for research news and analysis, dedicated coverage of the latest industry news, and research tools and resources for the ALS research community. The ALS Research Forum consists of ALS-related content developed through our partnership with the Alzforum, as well as independent news coverage, and a dynamic listing of current drug development efforts relevant to ALS. Additional resources include databases, such as ALSGene, listings of funding opportunities and scientific meetings, and research resources such as links to repositories and clinical trial registries. We aim for this portal to benefit both veteran ALS researchers and those new to the ALS field, and to provide relevant information for researchers in both academia and industry. We welcome your feedback and input as we work together to make this site a powerful tool to encourage more people to research ALS. https://www.
Frick Fonundation for ALS Research
FRICK FOUNDATION FOR ALS RESEARCH. The Frick Foundation is looking for talented early-career scientists who have already produced excellent supervised work, ready to work independently and shows potential to be a research leader. Two researchers will receive 100,000 Swiss francs each that can be used over 2 years. Researchers of any nationality with 5 years of experience since completion of their PhD, a scientific track record showing great promise and an excellent research proposal. Research must be conducted in a public or private research organisation. Applications should include: Name, address and title of proposal. Specific goals of the project and detailed reseach plan. List of papers published by the applicant of an academic institute during the past 5 years. A scientific and financial report will be required at the end of two years. Overheads and salary of the Principal Investigator are not included. Please send your application by e-mail for the deadline: 30 September 2021. Please no telephone calls or faxes You will receive a response in December 2021.
Research Opportunities at the Penn Comprehensive ALS Center
We belong to multiple national research consortia including NEALS and WALS. These memberships help keep us abreast of all of the latest clinical trials and afford us opportunities for participation and collaboration. The Penn ALS Research DatabaseCurrently RecruitingDesigned to collect demographic and clinical information for research purposes and store it in a secure database. Utilized to screen for clinical drug trials, epidemiologic investigations and other research studies. Longitudinal Study of Biomarkers and Functional Outcome Measures in Patients with Amyotrophic Lateral SclerosisCurrently Enrolling*Some visits occur at the Main campus at 3400 Spruce Street. There are also other clinical trials and investigations in the early planning stages. If you are interested in learning more about any of these research opportunities, please contact Kelly Almasy RN, CRC at 215-829-5041. Make an appointment at the Penn Comprehensive ALS Center. To make an expedited appointment with a Penn ALS neurologist, call 215-829-3053.
SOD1 is the first ALS gene to be discovered, and it affects about 2% of patients. When a change occurs in this gene, it can convert a protein in the body into a non-working or toxic form that damages nerves and surrounding cells. Scientists have focused on designing therapies that block the production of this damaging protein. Take that, SOD1! This treatment is called an antisense oligonucleotide, and it can be designed to block the production of any gene. A second discovery of a genetic mutation in gene C9ORF72 affects 10% of patients. Scientists have been working feverishly to figure out how these mutations cause ALS and how an ASO treatment could lower the toxic gene product created. Looking for the silver lining? The good news is this discovery proves that if we can identify additional genetic causes of ALS, we may be able to design similar strategies to tackle genetic mutations.
Basic Research, Clinical Trial Infrastructure, and Community Engagement to Support Drug Development for ALS
Basic Research, Clinical Trial Infrastructure, and Community Engagement to Support Drug Development for ALS. Meeting Objective: Most cases of ALS, a progressive neurodegenerative disease, have no known cause or cure. Disease pathophysiology is incompletely characterized-approximately 10% of ALS cases are linked to genetic biomarkers, while the other 90% of cases are classified as sporadic-presenting challenges in trial design and patient enrollment. While much progress has been made in basic and clinical ALS research to date, there is still an outstanding need for enhanced evidence generation on the safety and effectiveness of investigational ALS therapeutics across disease stages. In this workshop, the first in a two-part series, participants will discuss challenges impeding therapeutic development for ALS as well as ways to overcome them.
UMass ALS Cellucci Fund supports ALS research at UMass Medical School
Supporting the boldest research ideas in the interdisciplinary labs under the direction of Robert H. Brown Jr., DPhil, MD, one of the world’s foremost authorities on ALS. This year’s event will take place on Monday, Oct. 11. The UMass ALS Cellucci Fund has been accepted again by John Hancock’s non-profit marathon program, and has five bibs available for people like you, who want to help find a cure for ALS. Learn more. Synthetic microRNA treatment targets mutant SOD1 gene that causes ALS. UMass Medical School and Massachusetts General Hospital are the first to safely treat two research participants with a synthetic microRNA, delivered into the spinal fluid, designed to silence a human disease-causing gene. Details of the treatment appear in the New England Journal of Medicine.